Brief: FDA Grants Orphan Drug Designation To Maia Biotechnology For THIO As A Treatment For Glioblastoma
10/11/2023 12:10
Nov 10 (Reuters) - Maia Biotechnology Inc MAIA.A :
* FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY
FOR
THIO AS A TREATMENT FOR GLIOBLASTOMA
Source text for Eikon: ID:nBw3V5bv8a
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale